SAN DIEGO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, will host an investor ...

Cabinet Secretary for Lands, Public Works, Housing, and Urban Development, Alice Wahome, has reaffirmed the Ministry’s ...

AnaptysBio, Inc. (NASDAQ:ANAB) shareholders should be happy to see the share price up 13% in the last month. But that cannot eclipse the less-than-impressive returns over the last three years.

Shares of ANAB stock opened at $16.06 on Tuesday. The firm has a market cap of $488.71 million and a P/E ratio of -2.64. The firm’s 50 day moving average price is $17.05 and its 200-day moving ...

Wedbush analyst David Nierengarten maintained a Buy rating on AnaptysBio (ANAB – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $16.08.

AnaptysBio (NASDAQ:ANAB – Get Free Report)‘s stock had its “outperform” rating reaffirmed by equities researchers at Wedbush in a research note issued to investors on Monday,RTT News reports.

The firm increased its portfolio allocation in ANAB by 55.02% over the last quarter. Frazier Life Sciences Management holds 2,209K shares representing 7.26% ownership of the company. In its prior ...

After hours: 7:50:06 pm GMT-5 ...